Brief Dr. Suchart Chongprasert's CV

Dr. Suchart Chongprasert is a registered pharmacist in Thailand. Shortly after serving as a faculty member of the Faculty of Pharmacy, Prince of Songkla University since graduation, he was awarded a prestigious Royal Thai Government scholarship to pursue an advanced degree abroad. He earned his doctorate degree (Ph.D.) from School of Pharmacy, Purdue University, US. Immediately after graduation, he entered a post-doctoral program at the University of Colorado Health Sciences Center, CO, US. He was also graduated a bachelor's degree in law (LLB) from the Faculty of Law, Thammasat University, Thailand.

Before having been promoted to be Director, Bureau of Drug Control since 1 October 2017, he was Director, Post- marketing Control Division, where one of his responsibilities was to build up and strengthen the capacities of the local pharmaceutical industry by assuring the full compliance with PIC/S GMP Guide. He officially represents the Thai FDA as member of the PIC/S Committee since Thai FDA became the 49th Participating Authority of the PIC/S. In addition to GMP inspection, Dr. Chongprasert has actively engaged in international fora on drug regulation issues, including, for example, innovative regulatory framework for self-medication, regulatory pathways of biosimilars, Advanced Therapy Medicinal Products (ATMPs) or Regenerative Medicines, conditional early approval of medicines.

As Director, Bureau of Drug Control, Dr. Chongprasert has been seriously committed to the implementation of GRevP in a review process of drug product applications for marketing authorization. He has taught the concept of GRevP for Thai FDA personnel since 2016. He has worked with other sectors, including the pharmaceutical industry associations and academia to promote Thailand as APEC Center of Excellence (CoE) on GRM in the ASEAN Region.

Dr. Chongprasert has involved more in building up and strengthening the capacities of the GMP Inspectorate and Surveillance Office in Thai FDA to keep pace with a rapidly changing demand for GMP inspection of domestic and foreign drug manufacturers according to the latest PIC/S GMP Guide. He looks forward to collaborating with other regulatory authorities having a comparable GMP inspection system to minimize any unnecessary duplication of GMP inspection.